WhiteLab Genomics expands to the US

WhiteLab Genomics, announces its US presence by joining Bayer’s Life Science incubator in Cambridge, MA. Leveraging Bayer’s expertise, WhiteLab aims to accelerate drug development timelines and mitigate risks through AI-powered genomic analysis, marking a significant step in their mission to deliver life-saving therapies to the market.

Joining the Bayer Co.Lab in Cambridge is a pivotal next step towards our US expansion. Leveraging Bayer’s rich expertise, we are confident this environment is ripe for transformative opportunities in healthcare, offering invaluable insights into the forefront of gene and cell therapy innovations. We are honored that WhiteLab has been selected for this incredible opportunity.

– said David Del Bourgo, CEO and Co-Founder of WhiteLab Genomics.

Discover more here.